Silicon Nanoparticles With Lipid-Amino Acid Coatings for Controlled Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing delivery systems for pharmaceutical and cosmetic agents face challenges in achieving controlled and slow-release of active ingredients, stability of biological compounds, penetration into deeper skin layers, and biocompatibility issues, with silicon-based carriers often leading to uncontrolled OSA polymerization and safety concerns.
Innovation Solution
Treat silicon nanoparticles with phospholipids and/or charged lipids, along with amino acids like arginine and glycine, to control the release of bioactive agents, stabilizing the silicon to form orthosilicic acid (OSA) and preventing polymerization, ensuring controlled release and biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If silicon-based carrier material is used for controlled release delivery, then delivery control is improved, but uncontrolled OSA polymerization occurs causing safety concerns
Solution Approach 1:
The patent introduces amino acids (arginine, glycine, histidine, or proline) as intermediary substances that complex with orthosilicic acid to prevent uncontrolled polymerization. These amino acids act as mediators between the silicon carrier material and the biological system, controlling the polymerization process while maintaining safety and bioavailability during the controlled release period.
Solution Approach 2:
The patent controls the polymerization process by changing chemical parameters - specifically by adjusting pH levels and introducing amino acid complexes that modify the polymerization kinetics. This allows the system to maintain controlled release characteristics while preventing harmful uncontrolled polymerization of orthosilicic acid.
2Speed
If topical delivery systems are used to deliver active agents, then skin penetration is improved, but stability of biological compounds deteriorates
Solution Approach 1:
The patent creates a composite delivery system combining silicon carrier material with amino acid complexes. This composite structure provides both the penetration enhancement needed for effective skin delivery and the stability required to protect biological compounds during transit and release, resolving the contradiction between speed of delivery and compound stability.
3Duration of action of moving object
If conventional delivery systems are used for long-term delivery, then delivery duration is improved, but residency time on skin deteriorates
Solution Approach 1:
The patent employs silicon carrier materials that provide continuous, sustained release of active ingredients over extended periods. The amino acid complexes ensure this release is controlled and stable, maintaining therapeutic levels continuously without requiring frequent reapplication, thus achieving both long delivery duration and adequate skin residency time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for stable and controlled release of pharmaceutical or cosmetic agents, enhancing skin penetration and reducing safety risks by maintaining OSA in a bioavailable form, suitable for long-term delivery.
Implementation Method 1
Silicon has a structural role as a constituent of the protein-glycosaminoglycanes complexes found in the connective tissues matrix of mammals... Elemental silicon (Si) dissolves in an aqueous environment to form silicic acids
Implementation Method 2
treating the surface of the silicon nanoparticles with one or more phospholipids and/or one or more further, charged lipids... treating the surface of the silicon nanoparticles with at least one amino acid which is arginine and/or glycine
Implementation Method 3
treating the surface of the silicon nanoparticles with at least one amino acid which is arginine and/or glycine... stabilizing the silicon to form orthosilicic acid (OSA) and preventing polymerization
Implementation Method 4
To enable a wider range of active ingredients to be delivered topically, considerable research has been focused on development of strategies for temporarily disrupting the stratum corneum barrier in a controllable fashion, so that drugs can permeate in sufficient and predictable quantities
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for promoting the controlled binding and release of a bioactive or pharmaceutical agent from a composition comprising silicon nanoparticles, wherein the silicon nanoparticles comprise at least 50 % by weight silicon, the method comprising treating the surface of the silicon nanoparticles with at least one lipid, and treating the surface of the silicon nanoparticles with at least one amino acid, wherein the ratio of lipid to silicon isfrom1:1 to 15:1. Also related compositions and methods.